星空体育官方入口网站网址大全-登录入口官网

#Ultomiris#

6篇内容 | 762人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1581168, encodeId=57fa158116850, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, objectTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, objectType=article, longId=726365, objectId=c0f8e2636523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f8e2636523, replyNumber=0, likeNumber=37, createdTime=2022-05-09, rootId=0, userName=ms7474195563676018, userId=707d16724215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f8e2636523, moduleTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c0f8e2636523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581167, encodeId=a87a158116e5d, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, objectTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, objectType=article, longId=196488, objectId=a16319648829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16319648829, replyNumber=0, likeNumber=107, createdTime=2020-06-27, rootId=0, userName=ms7474195563676018, userId=707d16724215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16319648829, moduleTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a16319648829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581166, encodeId=1aeb1581166ec, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, objectTitle=ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价, objectType=article, longId=193433, objectId=e611193433d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e611193433d4, replyNumber=0, likeNumber=39, createdTime=2020-05-05, rootId=0, userName=ms7474195563676018, userId=707d16724215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e611193433d4, moduleTitle=ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e611193433d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581165, encodeId=3db1158116579, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, objectTitle=C5抑制剂Ultomiris（ravulizumab-cwvz）治疗重症COVID-19患者的临床试验：即将开展, objectType=article, longId=192701, objectId=46b6192e01ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46b6192e01ae, replyNumber=0, likeNumber=59, createdTime=2020-04-23, rootId=0, userName=ms7474195563676018, userId=707d16724215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46b6192e01ae, moduleTitle=C5抑制剂Ultomiris（ravulizumab-cwvz）治疗重症COVID-19患者的临床试验：即将开展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=46b6192e01ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581164, encodeId=81741581164bc, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, objectTitle=欧盟批准C5补体抑制剂ULTOMIRIS用于治疗阵发性睡眠性血红蛋白尿（PNH）成人患者, objectType=article, longId=174812, objectId=e3031e48124f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3031e48124f, replyNumber=0, likeNumber=45, createdTime=2019-07-06, rootId=0, userName=ms7474195563676018, userId=707d16724215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3031e48124f, moduleTitle=欧盟批准C5补体抑制剂ULTOMIRIS用于治疗阵发性睡眠性血红蛋白尿（PNH）成人患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e3031e48124f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581163, encodeId=5edb158116389, content=<a href='/topic/show?id=89a218120dc' target=_blank style='color:#2F92EE;'>#Ultomiris#</a>, objectTitle=Alexion的Ultomiris达到了非典型溶血性尿毒症综合征晚期研究的主要目标, objectType=article, longId=159162, objectId=d59815916279, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d59815916279, replyNumber=0, likeNumber=55, createdTime=2019-01-31, rootId=0, userName=ms7474195563676018, userId=707d16724215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d59815916279, moduleTitle=Alexion的Ultomiris达到了非典型溶血性尿毒症综合征晚期研究的主要目标, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d59815916279)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Ultomiris

2020-05-29

ms7474195563676018 (审核中...)

前往app查看评论内容

#Ultomiris#

长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果

2022-05-09

ms7474195563676018 (审核中...)

前往app查看评论内容

#Ultomiris#

每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点

2020-06-27

ms7474195563676018 (审核中...)

前往app查看评论内容

#Ultomiris#

ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价

2020-05-05

ms7474195563676018 (审核中...)

前往app查看评论内容

#Ultomiris#

C5抑制剂Ultomiris（ravulizumab-cwvz）治疗重症COVID-19患者的临床试验：即将开展

2020-04-23

ms7474195563676018 (审核中...)

前往app查看评论内容

#Ultomiris#

欧盟批准C5补体抑制剂ULTOMIRIS用于治疗阵发性睡眠性血红蛋白尿（PNH）成人患者

2019-07-06

ms7474195563676018 (审核中...)

前往app查看评论内容

#Ultomiris#

Alexion的Ultomiris达到了非典型溶血性尿毒症综合征晚期研究的主要目标

2019-01-31

科室
- - 订阅+
  - 更多科室
工具
服务